Group 1 - The company held its sixth board meeting on August 15, 2025, where all six attending directors approved the resolutions [2][3][4] - The board approved the use of idle funds from a specific stock issuance to temporarily supplement working capital and for cash management [3][4][17] Group 2 - The company raised a total of approximately 275 million yuan from the issuance of 20,146,514 shares at a price of 13.65 yuan per share, with a net amount of about 268.89 million yuan after deducting issuance costs [7][18] - As of June 30, 2025, the company had utilized 60 million yuan of the raised funds, leaving a balance of approximately 21.05 million yuan [8][20] - The company plans to use up to 100 million yuan, which is 37.19% of the net raised funds, to temporarily supplement working capital for a period not exceeding 12 months [11][12] Group 3 - The company intends to use up to 90 million yuan of idle funds for cash management, focusing on safe and liquid investment products [17][22] - The cash management will not affect the normal operation of the fundraising projects and is expected to enhance the efficiency of fund usage [30][31]

Core Viewpoint - Dongguan Securities has issued a verification opinion regarding Te Yi Pharmaceutical Group's plan to manage idle funds raised from a specific stock issuance in 2023, emphasizing the importance of efficient fund utilization while ensuring that the investment projects proceed normally [1][5]. Fundraising Overview - Te Yi Pharmaceutical raised a total of RMB 268,891,257.70 from issuing 20,146,514 shares at RMB 13.65 per share, after deducting issuance costs of RMB 874,949.91 [1][2]. - As of June 30, 2025, the company has utilized RMB 60 million of the raised funds, leaving a balance of RMB 210.48 million, which includes net interest income of RMB 1.6378 million [2]. Fund Usage and Idle Reasons - The company has temporarily supplemented working capital with RMB 200 million, which has been fully returned to the special account for raised funds [2]. - The idle funds are primarily due to the construction cycle of the modern Chinese medicine product line expansion and technology upgrade project, which has resulted in a temporary surplus of funds [2]. Cash Management Plan - The company plans to use up to RMB 90 million of the idle funds for cash management, focusing on high liquidity and safety investment products such as structured deposits and time deposits, with a maximum investment period of 12 months [3][4]. - The management will ensure that cash management does not affect the normal progress of investment projects [3]. Decision-Making Process - The board of directors has approved the cash management plan, ensuring compliance with relevant laws and regulations, and allowing for the rolling use of funds within the specified limits [4][5]. Verification Opinion - Dongguan Securities has confirmed that the cash management plan aligns with legal requirements and will not impact the company's main business operations, thereby enhancing the efficiency of idle fund utilization and potentially increasing company returns [5].

Core Viewpoint - Dongguan Securities has conducted a thorough review of the temporary use of idle funds raised by Te Yi Pharmaceutical Group Co., Ltd. through a simplified procedure for issuing shares to specific targets in 2023, confirming compliance with relevant regulations and the necessity of the fund usage [1][7][8] Fundraising Basic Situation - Te Yi Pharmaceutical received approval from the China Securities Regulatory Commission on September 4, 2023, to issue shares, raising a net amount of approximately RMB 268.89 million after deducting issuance costs [1] - The funds have been fully received and verified by Da Xin Accounting Firm on September 15, 2023 [1] Fund Usage and Idle Reasons - As of June 30, 2025, the company has utilized RMB 60 million of the raised funds, leaving a balance of RMB 210.48 million, which includes net interest income [2] - The idle funds are primarily due to the construction cycle required for the modernization of traditional Chinese medicine product lines and technology upgrades [3] Previous Use of Idle Funds - On December 26, 2024, the company’s board approved the temporary use of up to RMB 200 million of idle funds for working capital, which has since been fully returned to the dedicated fundraising account by July 2, 2025 [4][5] Current Proposal for Idle Funds - The company plans to temporarily use up to RMB 100 million (37.19% of the net amount raised) of idle funds for working capital, with a repayment period not exceeding 12 months [5][7] - This usage aims to enhance fund efficiency, reduce financial costs, and maintain the interests of the company and its shareholders [6][8] Review and Approval Process - The board has approved the plan to use idle funds, ensuring compliance with relevant regulations and confirming that it will not affect the implementation of original fundraising projects [7][8]

Group 1 - The company announced the approval of two proposals by its sixth board of directors' second meeting, which include the temporary use of idle raised funds for supplementing working capital and cash management [2] - The proposals involve utilizing part of the funds raised through a simplified procedure for specific targets in the year 2023 [2] - The announcements indicate the company's strategic approach to managing its financial resources effectively [2]

特一药业（SZ 002728，收盘价：9.28元）8月15日晚间发布公告称，公司第六届第二次董事会会议于 2025年8月15日在公司会议室采用现场及电子通信方式召开。会议审议了《关于使用2023年度以简易程 序向特定对象发行股票部分闲置募集资金进行现金管理的议案》等文件。 （文章来源：每日经济新闻） 2024年1至12月份，特一药业的营业收入构成为：医药工业占比97.65%，医药商业占比1.38%，化工产 品及其他占比0.98%。 ...

特一药业集团股份有限公司 关于使用 2023 年度以简易程序向特定对象发行股票部分 闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002728 证券简称：特一药业 公告编号：2025-054 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 8 月 15 日召开第六届董事会第二次会议，审议通过了《关于使用 2023 年度以简易程序向特 定对象发行股票部分闲置募集资金暂时补充流动资金的议案》，现就使用 2023 年度以 简易程序向特定对象发行股票部分闲置募集资金暂时补充流动资金的相关事宜公告如 下： 一、募集资金基本情况 特一药业集团股份有限公司于 2023 年 9 月 4 日收到中国证券监督管理委员会出具 的《关于同意特一药业集团股份有限公司向特定对象发行股票注册的批复》（证监许可 [2023]1987 号），同意公司以简易程序向特定对象发行股票的注册申请。公司本次发 行数量为 20,146,514 股，发行价格为 13.65 元/股，募集资金总额 274,999,916.10 元， 扣 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-055 特一药业集团股份有限公司 关于使用 2023 年度以简易程序向特定对象发行股票部分 闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 8 月 15 日召开第六届董事会第二次会议，审议通过了《关于使用 2023 年度以简易程序向特 定对象发行股票部分闲置募集资金进行现金管理的议案》，同意公司在保证不影响 2023 年度以简易程序向特定对象发行股票募集资金投资项目建设和募集资金使用的情况下， 使用不超过人民币 9,000 万元的暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好、保本型的投资产品，使用期限自董事会审议通过之日起 12 个月内有效。在 上述额度及期限范围内，资金可以滚动使用。 根据《上市公司募集资金监管规则》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，上述事 项在董事会审批权限内，无需提交公司股 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-053 1、审议通过《关于使用 2023 年度以简易程序向特定对象发行股票部分闲置募集 资金暂时补充流动资金的议案》 具体详见公司同日刊登于巨潮资讯网的《关于使用 2023 年度以简易程序向特定对 象发行股票部分闲置募集资金暂时补充流动资金的公告》。 （表决结果：同意票 6 票，反对票 0 票，弃权票 0 票） 2、审议通过《关于使用 2023 年度以简易程序向特定对象发行股票部分闲置募集 资金进行现金管理的议案》 特一药业集团股份有限公司 关于第六届董事会第二次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）第六届董事会第 二次会议于 2025 年 8 月 15 日 10：00 在公司会议室采用现场及电子通信方式召开，会 议通知于 2025 年 8 月 13 日以电子邮件方式发出，会议应出席董事 6 名，实际出席 6 名。公司非董事高级管理人员列席了本次会议。会议的召集、召开符合《公司法》和《公 ...

东莞证券股份有限公司 关于特一药业集团股份有限公司 使用 2023 年度以简易程序向特定对象发行股票部分闲置募集资金 进行现金管理的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023年度以简易程序向特定对象 发行股票的保荐机构，根据《上市公司募集资金监管规则》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等 法律法规的有关规定，对特一药业拟使用2023年度以简易程序向特定对象发行股票部分 闲置募集资金进行现金管理的情况进行了审慎核查，并出具本核查意见。核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意特一药业集团股份有限公司向特定对象发行 股票注册的批复》（证监许可【2023】1987号）同意注册，公司向9家特定投资者发行 人民币普通股20,146,514股，发行价格为每股13.65元。截至2023年9月14日，本公司实 际以简易程序向特定对象发行人民币普通股（A股）20,146,514股，募集资金总额 274,999,916.10元，扣除承销费 ...

东莞证券股份有限公司 关于特一药业集团股份有限公司 使用 2023 年度以简易程序向特定对象发行股票部分闲置募集资金暂时补 充流动资金的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023 年度以简易程序向特定对象 发行股票的保荐机构，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》和《上市公司募集资金监管规则》 等有关规定，东莞证券对公司使用 2023 年度以简易程序向特定对象发行股票部分闲置 募集资金暂时补充流动资金的情况进行了认真、审慎核查。核查的具体情况如下： 一、募集资金的基本情况 | 序 | 项目名称 | 融资项目名称 | | 调整后拟投 入募集资金 | 募集资金 累计投入 | 累计投 入比例 | 项目预定可使 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | （万元） | 金额 （万元） | （%） | 用状态日期 | | 1 | 补充流动 资金 | 2023 | 年度以简 ...